Zocitab
Zocitab

13.62
A generic medicine indicated for women’s health and oncology care. Addresses abnormal cellular growth by interfering with the synthesis of genetic material.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Capecitabine
Reference Brand
Capecitabine
Product Origin
Generic Brand
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Pain Relief, Oncology Support
Product Category
Fluoropyrimidine Carbamate
Pharmacological Class
Antineoplastic
Manufacturer Description
Formulated to alleviate neoplastic cellular growth to support cancer remission and target tumor cell proliferation.
Mechanism of Action
Enzymatically converts to 5-fluorouracil in tumor cells, inhibiting thymidylate synthase to block DNA synthesis.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12–24 hours
Contraindications
Severe renal impairment, Known dihydropyrimidine dehydrogenase (DPD) deficiency
Severe Adverse Events
Severe cardiotoxicity — requires immediate medical attention, Severe diarrhea with dehydration — requires immediate medical attention
Common Side Effects
Nausea, Diarrhea, Vomiting
Uncommon Side Effects
Hand-foot syndrome, Fatigue, Myelosuppression
Drug Interactions
Warfarin, Phenytoin, Leucovorin
Pregnancy Safety Warnings
TGA Category D: High risk of fetal toxicity. Strictly contraindicated in pregnancy. Breastfeeding: Contraindicated.
Age Restrictions
Approved for adults.
Storage Guidelines
Store below 25°C. Keep dry.
Information related to Zocitab is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
where to order Antiplatelet Tablets - Pradaxa Australia